ArticleBMJ open2025
Correlation of anti-phosphatidylethanolamine antibodies with premature birth in women with a history of miscarriage: a retrospective study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel Clinically Validated Machine Learning Model for Early Pregnancy Loss in Recurrent Spontaneous Abortion: Integrating Serum Autoantibodies and Ultrasonic Parameters.International journal of general medicine · 2026Article
- How microbiota influence maternal blood disorder in miscarriage.Molecular biology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective is to examine the correlation of anti-phosphatidylethanolamine (aPE) antibodies with premature birth. Premature birth is an important risk factor for infant mortality and subsequent development of mental, metabolic and cardiovascular diseases. However, the risk factors associated with preterm birth are not well understood. aPE antibodies are an anti-phospholipid autoantibody that is thought to be a factor in pathological pregnancy. However, aPE antibodies have not been included in the classification criteria for antiphospholipid syndrome. Therefore, we aimed to check the clinical significance of aPE antibodies in association with premature birth.
designWe conducted a retrospective analysis of 442 pregnant women who had experienced at least one unexplained miscarriage and were tested for aPE antibodies and compared their clinical characteristics, coagulation indicators, immune biomarkers and pregnancy outcomes. Logistic regression analysis was employed to identify factors associated with premature birth.
settingRuian City, Wenzhou, Zhejiang Province, China.
participantsA total of 442 patients with ultrasound-confirmed intrauterine pregnancy from the Third Affiliated Hospital of Wenzhou Medical University between May 2018 and December 2022 were retrospectively selected and included in the study. The inclusion criteria were as follows: having been tested for aPE and having experienced at least one unexplained miscarriage. The exclusion criteria were as follows: (a) incomplete clinical records, (b) being positive for typical antiphospholipid antibodies (aPL, aβ2-GP1 and LA), (c) hormone or metabolic disorder, (d) lost to follow-up, (e) known clinical autoimmune diseases, (f) severe reproductive system infection or malformation, (g) fetal loss: pregnancy loss before 24 weeks and (h) multiple pregnancy. In this study, preterm birth was defined as birth before 37 weeks. PRIMARY AND SECONDARY OUTCOME MEASURES: We enrolled 442 patients in our study: 60 pregnancies with premature birth and 382 pregnancies with term birth.
resultsOur findings revealed that among the 442 participants, 13.6% had a premature birth (<37 weeks). Elevated aPE antibody levels were independently associated with an increased risk of premature birth. Multivariate logistic regression showed that the OR for premature birth was significant across all models, with the highest OR observed in the fully adjusted model (OR=1.19; 95% CI: 1.12 to 1.27). No significant interactions were found in any subgroups after stratifying by age, body mass index, previous miscarriage, complement C3, homocysteine and fibrinogen. The analysis revealed a linear relationship between aPE antibodies and premature birth.
conclusionOur findings suggest that aPE antibodies may be independent risk factors for premature birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.